SX-fraction: Promise for novel treatment of type 2 diabetes

Table 1 Changes in diabetic parameters after 1 wk of “feed-switch” in mice

Parameters	(Former) Control→ +SXF	(Former) SXF→Control
Glc (mg/dL)	400→155a	180→365a
Ins (U/mL)	790→20a	120→990a
Tgl (mg/dL)	560→125a	230→620a
Body weight (g)	46→41	34→37

^aP < 0.01 (note: No statistical differences in body weight). Glc: Serum glucose; Ins: Serum insulin; Tgl: Serum triglycerides; SXF: SX-fraction.

Table 2 Hypoglycemic effect of SX-fraction on patient newly diagnosed with type 2 diabetes

Diagnosis/Prognosis	FBG (mg/dL)	HbA1c (%)
Initial diagnosis	248	11.5
3rd month prognosis (with 2.5 mg glyburide and SXF)	80-90	5.2
5th month prognosis (with 1.25 mg glyburide and SXF)	80-90	N/D
9th month prognosis (with SXF only)	Approximately 90	5.6

N/D: Not determined. SXF: SX-fraction; FBG: Fasting blood glucose; HbA_1c: Glycosylated hemoglobin A_1c.

Table 3 Hypoglycemic effects of SX-fraction on type 2 diabetic patients

Patients	Age (yr)	Sex	FBG (mg/dL) Before SXFa	After SXFa	% of FBGdeclined with SXF
A	44	M	Approximately 260	90-100	Approximately 63
B	75	F	Approximately 200	110-130	Approximately 40
C	25	F	150-180	110-120	Approximately 30
D	37	M	180-200	120-140	Approximately 32
E	64	F	Approximately 220	130-150	Approximately 37
F	41	M	Approximately 210	100-110	Approximately 50
G	53	F	170-190	100-110	Approximately 42

^aBefore and after SX-fraction indicates the fasting blood glucose values measured at Day 0 and Day 28 of a trial, respectively. SXF: SX-fraction; FBG: Fasting blood glucose; M: Male; F: Female.